In addition, anti‐HER2 therapies such as the monoclonal antibody drugs trastuzumab and pertuzumab and the receptor tyrosine kinase inhibitor lapatinib have been employed for the treatment of HER2‐positive breast cancer [3]. This evidence concerns the gene ERBB2 and breast cancer.